allogene therapeutics logo

Allogene Therapeutics

We are a biotechnology company with a mission to catalyze the next revolution in cancer treatment through the development of allogeneic CAR T therapy. Allogene Therapeutics, a Two River portfolio company, is a startup biotech company developing of allogeneic chimeric antigen receptor T-cell (CAR T) therapy directed at blood cancers and solid tumors.

Allogene Therapeutics was formed by two ex-Kite executives, Arie Belldegrun, founder and former Chairman and David Chang, former CMO of Kite Pharma, through acquiring the rights to a portfolio of CAR-T development programs partially owned by Pfizer.

[stock_market_widget type=”leaderboard” template=”color-frame” color=”yellow” assets=”ALLO” api=”yf” style=”font-size: 15px”]

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttps://www.allogene.com
Founded2018
Disease Focus
Development StagePreclinical
STOCK CODENASDAQ: ALLO
Address
270 Littlefield Avenue, South San Francisco, CA 94080
California
United States
Email
Contact Number
650-457-2700

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/allogene-therapeutics” connections=”true” suffix=””]

Allogene is pursuing allogeneic CAR-T therapy, as opposed to the commercial autologous versions available now. Autologous therapy requires extracting T cells from patients blood, then genetically manipulating and re-infusing them into the patient. Allogeneic therapy would use T cells from compatible, health donors; in effect, one donors cells could treat many patients, and the therapy would be _off the shelf” ready for infusion upon diagnosis of a patient.

In April 2018, Allogene and Pfizer signed an asset contribution agreement for Pfizers allogeneic CAR T-cell therapy portfolio, which includes 16 preclinical assets and UCART19 from Pfizer-Cellectis collaboration pipeline. Under the terms, Pfizer will continue to participate financially in the development of the CAR T portfolio through a 25% ownership stake in Allogene. Pfizer continues to have an 8% ownership stake in Cellectis through an equity agreement entered into in 2014. Also, Cellectis will remain eligible to receive clinical and commercial milestone payments of up to $2.8 billion per target for 15 targets and royalties in the high single digits on net sales of any products that are commercialized by Allogene under the agreement.

In Apr 2018, Allogene received $300 Mn in Series A financings from an investment consortium that includes TPG, Vida Ventures, BellCo Capital, the University of California Office of the Chief Investment Officer and Pfizer, among others.